Hyperkalemia is a diseases in which levels of potassium are higher than normal level (3.5 and 5.0 mmol/L) in blood serum. Kidneys are responsible for managing potassium balance in the body by regulating its excretion as well as its intake. A person is prone to develop hyperkalemia when the consumption of potassium exceeds that of kidneys’ potential to excrete it. The right amount of potassium and sodium in the body play a vital role in normal functioning of the myocardium.
Hyperkalemia can occur due to congestive heart failure, chronic kidney disease, or diabetic kidney disease. The condition can also occur when a patient receives renin-angiotensin-aldosterone system inhibitors (RAAS) in kidney disease. Abnormal levels of potassium can lead to irregular heartbeats, which can be fatal. Hyperkalemia is diagnosed by kidney functioning test, creatinine blood test, blood tests, and glucose monitoring.
Hyperkalemia Treatment Market– Dynamics
Increase in prevalence of cardiac arrhythmias and chronic kidney disease are major factors driving growth of hyperkalemia treatment market during the forecast period. According to Centers for Disease Control and Prevention (CDC) report, in 2017 around 30 million or 15% people suffer from chronic kidney diseases in the U.S. Increasing number of people suffering from lifestyle-associated diseases also leads to high prevalence of hyperkalemia, which in turn boost growth of the market.
Hyperkalemia Treatment Market – Regional Insights
On the basis of geography, the global hyperkalemia treatment market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America is expected to hold dominant position in the global hyperkalemia treatment market followed by Europe during the forecast period.
The U.S. holds a dominant position in North America market due to development in healthcare infrastructure, and Unhealthy lifestyle of U.S of citizen. As incidence of hyperkalemia has been reported anywhere from 2.6% to 3.2% which is highest among others region.
Furthermore, Asia Pacific hyperkalemia treatment market is expected to witness significant growth due increasing launches of drugs for the treatment of hyperkalemia. For instance, In May 2018, The U.S. Food and Drug Administration (U.S FDA) approved AstraZeneca’s, Lokelma a drug that is insoluble, non-absorbed sodium zirconium silicate, oral suspension and acts as a highly-selective potassium-removing agent for the treatment of hyperkalemia in adults.
Similarly, in October 2015, the U.S FDA approved Relypsa, Inc.’s., Veltassa a drug to treat hyperkalemia.
Hyperkalemia Treatment Market - Competitive Landscape
Major players operating in the hyperkalemia treatment market include, AstraZeneca, Klarvoyant Biogenics Pvt. Ltd, Concordia Pharmaceuticals Inc, Steadfast MediShield Pvt. Ltd, Perrigo Company plc, AdvaCare Pharma, Eli Lilly and Company, Carolina Medical Products, Relypsa, Inc., RSM Kilitch Pharma Pvt. Ltd, Novel Laboratories, and others.
Hyperkalemia Treatment Market – Taxonomy
On the basis of drug type, the global hyperkalemia treatment market is segmented into:
On the basis of route of administration, the global hyperkalemia treatment market is segmented into:
On the basis of distribution channel, the global hyperkalemia treatment market is segmented into:
On the basis of geography, the global hyperkalemia treatment market is segmented into: